Возраст домена | 20 лет |
Дата окончания | Истек срок регистрации |
PR | 2 |
ИКС | |
Страниц в Google | 1530 |
Страниц в Яндексе | 136 |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 5412447 |
Alexa Country | Нет данных |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
New Evidence | A medical publishing company focused on bringing you data from pivotal international research presented today that can impact practice tomorrow.
n/a
n/a
UTF-8
72.79 КБ
398
3 339 симв.
2 850 симв.
Данные предоставлены сервисом semrush
Сайт | Общие фразы | PR | тИЦ | Alexa Rank | Alexa Country | |
---|---|---|---|---|---|---|
![]() |
3 | 3 |
0 | 3988225 | ![]() |
|
![]() |
3 | 3 |
10 | 2061477 | ![]() | |
![]() |
3 | 4 |
0 | 574244 | ![]() | |
![]() ![]() |
3 | 4 |
0 | 16736842 | ![]() |
|
![]() |
3 | 3 |
0 | 5341381 | ![]() |
|
![]() ![]() |
2 | 6 |
0 | Нет данных | ![]() |
|
![]() |
1 | n/a | 0 | Нет данных | ![]() |
|
![]() |
1 | n/a | 0 | Нет данных | ![]() |
|
![]() |
1 | 2 |
0 | Нет данных | ![]() |
|
![]() |
1 | 1 |
0 | Нет данных | ![]() |
|
Еще 40 сайтов после авторизации |
Данные предоставлены сервисом semrush
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
![]() | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 9 Февраля 2015 ) | |
Количество ссылок на сайт | 6 |
Количество доменов, которые ссылаются на сайт | 5 |
Количество найденных анкоров | 4 |
Исходящие (внешние) ссылки домена | 6 |
Количество доменов, на которые ссылается сайт | 2 |
Количество исходящих анкоров | 2 |
Внешние ссылки главной страницы ( 5 ) | |
twitter.com/newevidence | |
linkedin.com/company/new-evidence | |
youtube.com/channel/UCXnOnSQOZOjMcWx9aRwXUWQ | Youtube |
elegantthemes.com | Elegant Themes |
wordpress.org | WordPress |
Внутренние ссылки главной страницы ( 37 ) | |
newevidence.com/oncology/ | <img> |
# | Specialties |
newevidence.com/oncology/breast/ | Breast |
newevidence.com/oncology/other/colorectal/ | Colorectal |
newevidence.com/oncology/genitourinary/ | Genitourinary |
newevidence.com/oncology/gynecological/ | Gynecological |
newevidence.com/oncology/other/headneck-2/ | Head/Neck |
newevidence.com/oncology/leukemias/ | Leukemias |
newevidence.com/oncology/lung/ | Lung |
newevidence.com/oncology/lymphomas/ | Lymphomas |
newevidence.com/oncology/melanoma/ | Melanoma |
newevidence.com/oncology/multiple-myeloma/ | Multiple Myeloma |
newevidence.com/oncology/pancreatic-cancer/ | Pancreatic Cancer |
newevidence.com/oncology/supportive-care/ | Supportive Care |
newevidence.com/oncology/journals/ | Journals |
newevidence.com/oncology/videos/ | Videos |
newevidence.com/oncology/papers/ | Papers |
newevidence.com/oncology/slides/ | Slides |
newevidence.com/oncology/wp-content/uploads/2018/03/ne_onc-i... | View latest journal |
newevidence.com/oncology/dr_neesha_dhani_discusses_dose_modi... | Dr. Neesha Dhani discusses dose modification of nanoliposomal irinotecan plus 5-FU/LV in NAPOLI-1 |
newevidence.com/oncology/dr_yoo_joung_ko_discusses_subgroup_... | Dr. Yoo-Joung Ko discusses subgroup analysis by measurable metastatic lesion number and selected lesion locations at baseline in... |
newevidence.com/oncology/phase-ii-lapact-trial-of-nab-paclit... | Phase II LAPACT trial of nab-paclitaxel plus gemcitabine for patients with locally advanced pancreatic cancer |
newevidence.com/oncology/a-real-world-multicentre-study-of-f... | A real-world multicentre study of first- and second-line treatment patterns and outcomes in advanced pancreatic cancer in Canada |
newevidence.com/oncology/impact-of-dose-modifications-of-nan... | Impact of dose modifications of nanoliposomal irinotecan plus 5-fluorouracil/leucovorin on efficacy in NAPOLI-1 |
newevidence.com/oncology/dr_yoo_joung_ko_discusses_subgroup_... | Dr. Yoo-Joung Ko discusses subgroup analysis results from NAPOLI-1 |
newevidence.com/oncology/case-studies-in-stage-iii-nsclc-a-s... | Case Studies in Stage III NSCLC: A Summary of the Presentation by Dr. Nancy Nixon |
newevidence.com/oncology/osimertinib-first-line-or-second-li... | Osimertinib: First-line or second-line therapy for EGFR M+ NSCLC? A Summary of the Debate between Dr. Peter Ellis and Dr. Barba... |
newevidence.com/oncology/are-all-pd-1-monoclonal-antibodies-... | Are all PD-1 Monoclonal Antibodies Equally Efficacious in Advanced NSCLC? A Summary of the Debate between Dr. Penelope Bradbury... |
newevidence.com/oncology/the_benda_eam_conditioning_regimen_... | The Benda-EAM Conditioning Regimen Prior to ASCT – A Canadian Perspective by Dr. Mohamed Elemary |
newevidence.com/oncology/lymphoma/ | Lymphoma |
newevidence.com/oncology/a-canadian-perspective-on-apl-treat... | A Canadian Perspective on APL Treatment by Dr. Matthew Seftel |
newevidence.com/oncology/leukemia/ | Leukemia |
newevidence.com/oncology/a-canadian-perspective-by-dr-michae... | A Canadian Perspective by Dr. Michael Ong on the KEYNOTE-045 and KEYNOTE-052 trials that assessed the efficacy and safety of pem... |
newevidence.com/oncology/best-practice-cases/ | Best Practice Cases |
newevidence.com/oncology/subscribe/ | Subscribe |
newevidence.com/oncology/about-us/ | About Us |
newevidence.com/oncology/contact-us/ | Contact Us |
Domain Name: newevidence.com
Registry Domain ID: 105386330_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.webnames.ca
Registrar URL: https://www.webnames.ca
Updated Date: 2015-09-02T02:50:59Z
Creation Date: 2003-10-21T06:16:07Z
Registrar Registration Expiration Date: 2016-10-21T06:16:07Z
Registrar: WEBNAMES.CA INC
Registrar IANA ID: 456
Registrar Abuse Contact Email: abuse@webnames.ca
Registrar Abuse Contact Phone: +1.8662217878
Domain Status: clientTransferProhibited
Registry Registrant ID:
Registrant Name: Paul Borlinha
Registrant Organization: SAGE Medica Inc
Registrant Street: 67 Mowat Avenue, Suite 200
Registrant City: Toronto
Registrant State/Province: ON
Registrant Postal Code: M6K 3R5
Registrant Country: CA
Registrant Phone: +1.4165031471
Registrant Phone Ext:
Registrant Fax: +1.4165031927
Registrant Fax Ext:
Registrant Email: paul@sagemedica.com
Registry Admin ID:
Admin Name: Paul Borlinha
Admin Organization: SAGE Medica Inc
Admin Street: 67 Mowat Avenue, Suite 200
Admin City: Toronto
Admin State/Province: ON
Admin Postal Code: M6K 3R5
Admin Country: CA
Admin Phone: +1.4165031471
Admin Phone Ext:
Admin Fax: +1.4165031927
Admin Fax Ext:
Admin Email: paul@sagemedica.com
Registry Tech ID:
Tech Name: Yaneisy Montero
Tech Organization: SAGEmedica Inc
Tech Street: 67 Mowat Avenue, Suite 200
Tech City: Toronto
Tech State/Province: ON
Tech Postal Code: M6K 3R5
Tech Country: CA
Tech Phone: +1.6475028171
Tech Phone Ext:
Tech Fax: +1.4165031927
Tech Fax Ext:
Tech Email: yaneisy@sagemedica.com
Name Server: ns1.cloudtodns.com
Name Server: ns2.cloudtodns.com
Name Server: ns3.cloudtodns.com
Name Server: ns4.cloudtodns.com
For more information on Whois status codes, please visit https://www.icann.org/resources/pages/epp-status-codes-2014-06-16-en/
>>> Last update of WHOIS database: 2015-09-02T02:50:59Z <<<
США - 199.34.228.55
Weebly
Weebly
HTTP/1.1 200 OK
Date: Sun, 12 Jan 2020 20:01:07 GMT
Server: Apache
Expires: Thu, 19 Nov 1981 08:52:00 GMT
Cache-Control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0
Pragma: no-cache
Link: ; rel="https://api.w.org/", ; rel=shortlink
Set-Cookie: PHPSESSID=u5bv375jiv8rlfj7u2lumm6cn5; path=/
Transfer-Encoding: chunked
Content-Type: text/html; charset=UTF-8
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"